摘要
目的观察依达拉奉治疗急性脑梗死的疗效及对血清炎性因子水平的影响。方法将2016年6月至12月收治的急性脑梗死患者96例随机分为治疗组和对照组,各48例。对照组采用脑部营养、抗血小板聚集和脱水等常规治疗,治疗组在常规治疗基础上加用依达拉奉,比较两组患者治疗前后血清白细胞介素8(IL-8)、肿瘤坏死因子-α(TNF-α)水平及临床疗效。结果与治疗前比较,两组患者治疗后血清IL-8和TNF-α水平均显著改善,且治疗组显著低于对照组(P<0.05);治疗组总有效率为91.67%,显著高于对照组的72.91%(P<0.05);治疗1,2,3个月后,两组患者美国国立卫生研究院卒中量表(NIHSS)评分均显著降低,且治疗组降幅显著高于对照组(P<0.05)。结论依达拉奉治疗急性脑梗死效果明显,并能降低血清炎性因子水平。
Objective To observe the clinical effect of edaravone in treating acute cerebral infarction and its effect on serum inflamma-tory factors. Methods Totally 96 patients with acute cerebral infarction admitted to our hospital from June to December in 2016 were randomly divided into the treatment group and the control group,48 cases in each group. The control group was treated with conventional therapy such as brain nutrition, antiplatelet therapy and dehydration, on the basis, the treatment group was treated with edaravone. The levels of serum IL - 8 and TNF -α before and after treatment, and the clinical efficacy were compared between the two groups. Results After treatment, the levels of serum IL -8 and TNF -α were significantly improved in the two groups, and those in the treat-ment group were significantly lower than those in the control group （P 〈 0.05）. The total effective rate of the treatment group was 91. 67% , which was significantly higher than 72.91% of the control group （ P 〈 0. 05）. After treatment for 1,2,3 months, the scores of NIHSS in the two groups were significantly lower than before treatment,and the observation group were significantly lower than those in the control group （P 〈 0.05）. Conclusion Edaravone is effective in the treatment of acute cerebral infarction, and can reduce the level of serum inflammatory factors.
作者
刘洪涛
刘又榕
梁海山
谢常燕
黄鹏
奚振华
Liu Hongtao;Liu Yourong;Liang Haishan;Xie Changyan;Huang Peng;Xi Zhenhua(The First People＇s Hospital of Nankang, Ganzhou, Jiangxi, China 341400)
出处
《中国药业》
CAS
2017年第22期47-49,共3页
China Pharmaceuticals
